MarketMoodz
Medicare Targets 15 High-Cost Drugs for 2028 Price Talks
Medicare has selected 15 high-cost drugs for government price negotiations, including therapies administered in doctors’ offices, with talks set to begin in 2026 and prices taking effect in January 2028. The move, rooted in the Inflation Reduction Act, could reshape drug affordability for seniors and alter pharma margins.
Key Takeaways
- CMS has selected 15 high-cost drugs for 2028 price negotiations, including drugs administered in doctors’ offices.
- Negotiations will start in 2026 and the negotiated prices take effect in January 2028.
- Companies may opt out of negotiations but would face a federal excise tax; opt-out is expected to be financially unlikely.
- Under the Inflation Reduction Act, Medicare has authority to set lower prices for high-cost drugs, with prior-cycle data suggesting meaningful savings.
- The third-cycle list includes Tradjenta designated for renegotiation.
People Involved
- Chiquita Brooks-LaSureCMS Administrator
- Joseph WolkCFO, Johnson & Johnson
Entities Involved
- Center for Medicare & Medicaid Services (CMS)U.S. government agency implementing price negotiations
- Inflation Reduction Act (IRA)Legislation enabling Medicare price negotiations
- Pharmaceutical industry (developers of the listed drugs)Developers of the 15 drugs under negotiation
MarketMoodz Analysis
For investors, the news signals ongoing regulatory risk to pharma pricing and potential near-term earnings implications for high-cost biologics and specialty drugs. The inclusion of drugs administered in clinical settings broadens the scope of the negotiation, potentially compressing margins across a wider slice of the portfolio.
Historically, the program is the IRA-driven price negotiation framework aimed at lowering drug costs. In the January 2025 cycle, CMS identified 15 drugs, and had 2024 prices been in effect, Medicare would have saved about $8.5 billion in net drug costs, roughly a 36% reduction, highlighting the sizable impact of negotiated pricing on spend.
What to watch next includes the official CMS list release, the 2026 negotiation outcomes, and the 2028 price implementation, along with any opt-out take-up and the practical effects on drug access, formulary coverage, and corporate margins.
Source: Original Article
Get AI-Powered Market Insights
Stay ahead of market-moving events with our real-time analysis and stock ratings.
Start Your Free Trial